Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trialHiddo J.L. Heerspink, Rey Isidto, John J.V. McMurray et al.|Nephrology Dialysis Transplantation|2019Cited by 216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C. Wheeler, Hiddo J.L. Heerspink, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2020Cited by 189
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trialOfri Mosenzon, Stephen C. Bain, Hiddo J.L. Heerspink et al.|Diabetes Obesity and Metabolism|2020Cited by 24
Author response for "Cardiovascular and renal outcomes by baseline albuminuria status and renal function — results from the <scp>LEADER</scp> randomized trial"Ofri Mosenzon, Itamar Raz, Stephen C. Bain et al.|Unknown|2020Cited by 0